All News

#RNL2024 @RheumNow @lihi_eder on enthesitis - ~1/3 PsA, SpA - Enthesitis precedes onset of PsA in PsO, high u/s score ass. w/ RFs (BMI, nail dyst) - Exam: tenderness (non-specific), as swelling uncommon. U/s helpful, but non-specif - Marker of severity, higher risk of damage

Eric Dein ericdeinmd ( View Tweet)

Dr. @lihi_eder recommends enthesial evaluation with POC ultrasound if available in addition to her clinical evaluation. #RNL2024 @RheumNow https://t.co/LQiyFK5VB1

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Goodbye AS. Eric Ruderman #RNL2024 @RheumNow https://t.co/FThKwuP3M6

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Enthesitis precedes the onset of PsA in PsO patients. Dr. @lihi_eder discusses the importance of US in evaluation of these patients. #RNL2024 @RheumNow https://t.co/bPLR7zpNe2

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Thank you to all of the excellent #RNL2024 speakers! @Bweber04, Dr. Monica Guma, Dr. Hani Gabalawy, Dr. Connie Weyand, Dr. Lisa Stamp, @AlexisOgdie, @_AprilArmstrong, @lihi_eder, @JointMD, Dr. Kevin Winthrop, Dr. Bruce Strober, @BharatKumarMD, Dr. David Karp, @Kahlenberglab,… https://t.co/f6gzCwe7Xb https://t.co/2SY9mPqdkO

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
"The best part of #RNL2024 is the audience gets to ask the experts alot of questions" - Dr. P Dara commented how lectures are short and the Q&A sessions are long, giving people enough time to ask tough questions and get answers. @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

AS v nr-AxSpA for TNFi - no diff in response @JointMD @RheumNow #RNL2024 ADA: ASAS20 AS 58%, nr-AxSpA 52%, ASAS40 AS 39%, nr 36% (ATLAS, ABILITY-1) ETN: ASAS 20 59%/52%, ASAS50/40 44%/33% in p3 AS study v EMBARK CZP: RAPID-AxSpA - no diff bw AS & nr-AxSpA response in same trial https://t.co/Rau2CDYbY4

Links:

Eric Dein ericdeinmd ( View Tweet)
The ultimate treatment goal in LN is long term preservation of kidney function. Summary of part 3 of @andreafava brilliant talk. #RNL2024 @RheumNow https://t.co/vwiAbWEmRh

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Very insightful talk on Vasculitis and pregnancy by Catherine Sims. Pregnancy compatible medications. Remission state. Checking antibodies ; risk of transmission, pregnancy and fetal morbidity. #RNL2024 @RheumNow https://t.co/81NAN1ulO5

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#RNL2024 @RheumNow @JointMD on AxSpA SPEED study: roughly 1/2 AS have AxSpA, 1/2 have nr-AxSpA Are they similar: - Yes, but r-axSpA less F and more abnml CRP = Low progression of nr-AxSpA to AS - only 26% progressed in mean 10.6 yrs https://t.co/Vwf5HaMcgu

Links:

Eric Dein ericdeinmd ( View Tweet)
We all want to preserve kidney function in lupus nephritis and to have good none invasive method to do that is just great. Low IL-16 at 12 months predicted kidney survival at 3 years better than proteinuria. 👏 @andreafava and his team. #RNL2024 @RheumNow https://t.co/O0trWoAqZz

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Urine biomarkers ( IL-16, CD163,CD206), parallel internal activity in lupus nephritis and and its decline at 3 months , best predict 1 year response . Future is great for lupus nephritis , cant wait to start using them. Great work @andreafava #RNL2024 @RheumNow https://t.co/VIFMytHFyD

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Urine proteomics in lupus nephritis. Summary of part one of his amazing talk. @andreafava #RNL2024 @RheumNow https://t.co/h8Eda0ZWVE

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Neutrophil signature in proliferative lupus nephritis. @andreafava #RNL2024 @RheumNow https://t.co/tNFIhohSvP

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Cancer and Myositis #RNL2024 @RheumNow @DrLisaCS on Cancer screening: Risk stratify: dermatomyositis, NXP2, TIFy, <40yo, refractory, dysphagia, cutaneous necrosis at higher risk Enhanced risk stratification for those at risks, versus "basic screening" for lower risks https://t.co/3yy9Fx1pk8

Links:

Eric Dein ericdeinmd ( View Tweet)
Dr Christopher-Stine @DrLisaCS Factors which should influence (some very strongly) your cancer screening approach in myositis @RheumNow #RNL2024 https://t.co/BoyJLrVDwo

Links:

Richard Conway RichardPAConway ( View Tweet)
anti-Sp4 Ab may be protective against cancer in myositis pts who are TIF1-g positive - Dr. L Christopher-Stine #RNL2024 @rheumnow https://t.co/n7Ikn3llGH

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Continue to love this myositis diagram. Seems to be getting ever more complicated though! @DrLisaCS @RheumNow #RNL2024 https://t.co/eXz6144y3y

Links:

Richard Conway RichardPAConway ( View Tweet)
Cancer and Myositis #RNL2024 @RheumNow @DrLisaCS Dermatomyositis risks - TIF1y is highest risk, followed by NXP2 Protective features: childhood onset, ILD, arthralgias Cancer and myositis often present w/in 1 yr before or after Cancer is major cause of death

Eric Dein ericdeinmd ( View Tweet)

Are we overprescribing because guidelines may be skewed to favor the pharmaceutical industry? Interesting questions posed by Dr. A Kavanaugh #RNL2024 @rheumnow https://t.co/wEwHaWNY5k

Links:

TheDaoIndex KDAO2011 ( View Tweet)
×